Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis

Generated Narrative: Group 179785

version: 4; Last updated: 2023-12-04 20:30:06+0000

Profile: ComparatorDefinition

Artifact related artifact: No display for RelatedArtifact (type: cite-as; citation: ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179785. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179785. Computable resource at: https://fevir.net/resources/Group/179785.)

Artifact Title: ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis

Artifact URL: https://fevir.net/resources/Group/179785

Artifact Publisher: Computable Publishing LLC

Artifact Copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

Artifact Contact: support@computablepublishing.com

Artifact Author: Brian S. Alper:

org/fhir/uv/ebm/StructureDefinition/combination-method: any-of

Artifact Status: active

identifier: FEvIR Object Identifier/179785

name: ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis

description:

Description: usual-care pharmacologic thromboprophylaxis Note: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice. Note: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial.

type: Animal

membership: Definitional

characteristic

org/fhir/uv/ebm/StructureDefinition/characteristic-description:

ATTACC comparator arm

CharacteristicTiming

  • contextCode: Start of trial
  • offset: 0-14
  • text: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.

code: Defined by CodeableConcept

value: Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be more than half of the approved therapeutic dose for the treatment of venous thromboembolism.

exclude: false

characteristic

org/fhir/uv/ebm/StructureDefinition/characteristic-description:

ACTIV-4a comparator arm

CharacteristicTiming

  • contextCode: Start of trial
  • offset: 0-14
  • text: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.

code: Defined by CodeableConcept

value: Any one of enoxaparin, dalteparin, tinzaparin, fondaparinux, or heparin according to local preference. Dose of agent specified to be consistent with guidelines for low dose thromboprophylaxis.

exclude: false

characteristic

org/fhir/uv/ebm/StructureDefinition/characteristic-description:

REMAP-CAP comparator arm

CharacteristicTiming

  • contextCode: Start of trial
  • offset: 0-14
  • text: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.

code: Defined by CodeableConcept

value: Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be sufficient to result in therapeutic anticoagulation.

exclude: false